EGFR and non-small cell lung carcinoma: On the other hands, novel targeted therapies against NSCLC with EGFR exon 20 insertion mutations, such as poziotinib17, mobocertinib (TAK-788)18,19, and amivantamab (JNJ-61186372)20 have been developed in preclinical and early clinical trials.